Cavitation-Enhanced Drug Delivery and Immunotherapy, 2nd Edition

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (25 February 2024) | Viewed by 1350

Special Issue Editors


E-Mail Website
Guest Editor
Erik Jonsson School of Engineering and Computer Science, The University of Texas at Dallas, Richardson, TX 75080, USA
Interests: ultrasound; focused ultrasound; ultrasound contrast agents; drug delivery; sonoporation; sonopermeation
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Biomedical Ultrasonics, Biotherapies and Biopharmaceuticals Laboratory, University of Oxford, Oxford OX37DQ, UK
Interests: ultrasound-mediated drug delivery; cavitation monitoring techniques
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to the second volume of this Special Issue intended to highlight new developments in Cavitation-Enhanced Drug Delivery and Immunotherapy. This rapidly evolving field has been buoyed in recent years by the development of methods harnessing the activity of ultrasound-stimulated bubbles known as cavitation. When properly controlled, cavitation can help overcome physical barriers to drug delivery whilst providing readily measurable information for timely quantitative feedback and treatment guidance. Microbubble-assisted therapies have demonstrated impressive advancements in clinical trials and pre-clinical areas, including applications in neurology, oncology, cardiology, and beyond.

This Special Issue will cover topics including the design of new cavitation nuclei constructs, cavitation-assisted immunotherapies and immunomodulation, targeted drug or gene delivery, and dual microbubble imaging and therapeutic approaches. In addition to manuscripts that investigate applications in drug delivery and immunotherapy, we also welcome numerical and/or experimental mechanistic studies, including but not limited to single-cell or single-bubble studies that glean insight into the biophysics of this technology.

This Special Issue is open to original research and review articles. Prospective authors are encouraged to view the first volume (https://www.mdpi.com/journal/pharmaceutics/special_issues/Microbubbles_Delivery) to see the scope of the article's subject matter. We look forward to receiving your contributions.

Dr. Shashank Sirsi
Dr. Michael Gray
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ultrasound
  • microbubbles
  • immunotherapy
  • sonoporation
  • cavitation
  • targeted drug delivery
  • acoustics
  • focused ultrasound
  • immunomodulation

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

26 pages, 1983 KiB  
Review
Fundamentals and Applications of Focused Ultrasound-Assisted Cancer Immune Checkpoint Inhibition for Solid Tumors
by Sepideh Jahangiri and François Yu
Pharmaceutics 2024, 16(3), 411; https://doi.org/10.3390/pharmaceutics16030411 - 16 Mar 2024
Viewed by 1087
Abstract
Despite spectacular clinical successes across several cancer types, immune checkpoint inhibition is effective only in subgroups of patients and suffers from significant systemic toxicities, highlighting the need to understand and locally overcome the mechanisms of therapeutic resistance. Similarly to other therapeutics, immunotherapies face [...] Read more.
Despite spectacular clinical successes across several cancer types, immune checkpoint inhibition is effective only in subgroups of patients and suffers from significant systemic toxicities, highlighting the need to understand and locally overcome the mechanisms of therapeutic resistance. Similarly to other therapeutics, immunotherapies face delivery challenges (for example, antibodies need to reach their targets) and immunological barriers that are unique to solid tumors and their microenvironment. Interestingly, focused ultrasound (FUS), with or without microbubbles, which has been shown to enhance gene and drug delivery, notably in oncology, has been recently found to trigger immunological responses. In recent years, there has been a strong emphasis on understanding the biological and immunological effects of FUS for cancer therapy, and FUS is now emerging as an approach that can improve cancer immunotherapy. We herein review: (1) the immunological barriers implicated in ICI resistance; (2) the fundamentals of FUS +/− MB and the current knowledge on leveraging FUS +/− MB bioeffects for improving ICI therapy efficacy; (3) the immune profile of tumor models that have been successfully treated with FUS and ICI; and finally, (4) we discuss the challenges ahead for translating FUS and MB treatments to the clinic, highlighting the exciting perspectives for this new research area. Full article
(This article belongs to the Special Issue Cavitation-Enhanced Drug Delivery and Immunotherapy, 2nd Edition)
Show Figures

Figure 1

Back to TopTop